阿苯达唑治疗前后泡状棘球蚴病患者淋巴细胞亚群变化及临床意义

IMMUNOLOGICAL MARKER INDICATING THE CURATIVE EFFECTS OF TREATMENT IN AE PATIENTS USING ALBENDAZOLE

目的 探讨泡球蚴病患者经阿苯达唑治疗后 ,机体免疫应答的状态和对病程转归的影响。 方法 7例未治疗泡球蚴病患者 ,6例经阿苯达唑治疗 12个月泡球蚴病患者 ,6例经阿苯达唑治疗 2 4个月泡球蚴病患者和 18例非流行区健康人群 ,用 FCM分析了 CD3+ 、CD4 + 、CD8+ 、CD1 9+ 、CD38+ 、CD1 6 + 56 + 和 HL A- DR+ 细胞的数量。 结果 治疗 12个月后 ,患者 CD8+细胞数继续上升 (P<0 .0 1) ,CD4 + / CD8+比值进一步倒置 ;治疗 2 4个月后 ,CD4 +细胞数开始升高 (P<0 .0 5 ) ,CD8+ 细胞数下降 ,CD4 + / CD8+ 比值升高 (P<0 .0 5 ) ;CD1 9+ 细胞在治疗 2 4个月后显著性升高 (P<0 .0 5 ) ;CD38+ 和 HL A-DR+ 细胞在治疗 2 4个月后呈显著性下降 (P<0 .0 1)。 结论 泡球蚴病患者治疗后 ,CD8+ 细胞引起的免疫抑制状态有所减轻 ,机体的保护性免疫应答有所恢复。

Objective To explore immunological marker and the outcome of disease after pharmacological treatment in human AE using albendazole. Methods AE patients were treated with albendazole, 6 cases for 12 months, 6 cases for 24 months, 7 cases were not treated and 18 controls. CD 3+, CD 4+, CD 8+, CD 19 +, CD 38 +, CD 16+56 +, HLA-DR+ lymphocytes were analyzed using FCM. Results CD 8+ lymphocyte continuous increase, mean while CD 4+/CD 8+ ratio was gradually descent in group of treating for 12 months compared with group of no treatment. After treatment of 24 months, CD 4+ lymphocyte, CD 4+/CD 8+ ratio began rising, and CD 8+ lymphocyte decreased. CD 19 + lymphocyte was higher, and CD 38 + lymphocyte and HLA-DR+ lymphocytes were lower in group of treating for 24 months as compared with group of no treatment and treating for 12 months. CD 3+ lymphocyte and CD 56 + lymphocyte were not changed in all patients during treatment. Conclusion CD 8+ cell and T suppression response appeared weakness and T helper response got strong in AE patients treated with albendazole. T helper cell activation in protective immunity was recovered.